Clinical Benefits & The Löwenstein Difference

3 9

tment of obstructive sleep apnea h¹ sruhe (Germany)

6-456) 0-375) 34)** 30)**

)*** )*** )*** )** )*** 2)* )*** )*** )***

9)***

)***

Figure 3: Mean values of unintentional leak and number of values within different mean pressure levels based on analysis of 5-min-sections of all APAP therapy nights.

patients

ge. ients with a ng of 5-20

Conclusion • The prisma20A highly significantly reduces respiratory events in OSA without indication for inadequate pressure increases in spite of broad pressure limits up to 20 hPa. Due to the relatively low pressure levels the overall leakage also Figure 4: Relative amount of slow wave sleep (SWS), REM sleep and arousal index under APAP therapy for patients within different pressure quartiles (Q1-Q4). Pressure quartiles were chosen based on actual individual median pressures of all patients. • The prevalence of TE-CSA in this study is in accordance with published literature. The device’s pressure regulation in TE-CSA patients was not inadequately high, indicating that there was no relevant misclassification of central respiratory events. • A relative high portion of mixed and central apneas in the diagnostic PSG, indicative of disturbed breathing regulation, could possibly be a predictor for TE-CSA. remained low and did not negatively affect APAP therapy. • Higher pressures did not negatively impact sleep quality.

dian

ergent nificant.

next generation sourcing

Made with FlippingBook Online newsletter